Skip to main content
SpringerLink
Log in

Lactobacillus rhamnosus GG Exacerbates Intestinal Ulceration in a Model of Indomethacin-Induced Enteropathy

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis Bb12 (Bb12) were assessed for their potential to prevent indomethacin-induced ulceration in the small intestine of Sprague-Dawley rats. Rats were gavaged skim milk, LGG, or Bb12 twice daily for 14 days. Between days 7–14, rats were gavaged indomethacin (Indo; 6 mg/kg). At sacrifice, small intestine was scored for ulceration and sampled for histologic, immunohistochemical, and myeloperoxidase (MPO) analyses. Indo+LGG-treated rats exhibited a 2.3-fold increase in MPO activity and a 9.8-fold increase in ulceration area compared to Indo-treated controls; these parameters did not differ significantly between Indo+Bb12 and Indo-treated controls. Crypt cell apoptosis decreased by 82% in Indo+Bb12-treated and 55% in Indo+LGG-treated rats compared to Indo-treated controls. Proliferation increased by 209% in Indo+LGG-treated animals compared to Indo-treated controls. Bb12 did not reduce indomethacin-induced intestinal ulceration, whereas LGG actually increased some indicators of injury. LGG and Bb12, at the doses tested, cannot alleviate indomethacin-induced intestinal injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G (2002) Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 46:1–6

    Article  PubMed  CAS  Google Scholar 

  2. Green GA (2001) Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 3:50–60

    Article  PubMed  CAS  Google Scholar 

  3. Whittle BJ (2003) Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17:301–313

    Article  PubMed  CAS  Google Scholar 

  4. Singh G, Triadafilopoulos G (2005) Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 59:1210–1217

    Article  PubMed  CAS  Google Scholar 

  5. Hawcroft G, D’Amico M, Albanese C, Markham AF, Pestell RG, Hull MA (2002) Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23:107–114

    Article  PubMed  CAS  Google Scholar 

  6. Kokoska ER, Smith GS, Deshpande Y, Wolff AB, Miller TA (1998) Indomethacin increases susceptibility to injury in human gastric cells independent of PG synthesis inhibition. Am J Physiol 275:G620–628

    PubMed  CAS  Google Scholar 

  7. Whittle BJ (2004) Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 500:427–439

    Article  PubMed  CAS  Google Scholar 

  8. Patrignani P, Tacconelli S, Sciulli MG, Capone ML (2005) New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 48:352–359

    Article  PubMed  CAS  Google Scholar 

  9. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, et al (2002) COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122:1913–1923

    Article  PubMed  CAS  Google Scholar 

  10. Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790–804

    Article  PubMed  CAS  Google Scholar 

  11. Isolauri E, Kirjavainen PV, Salminen S (2002) Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 50(suppl 3):III54–59

    PubMed  Google Scholar 

  12. Gotteland M, Cruchet S, Verbeke S (2001) Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans. Aliment Pharmacol Ther 15:11–17

    Article  PubMed  CAS  Google Scholar 

  13. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202–1209

    Article  PubMed  Google Scholar 

  14. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M (2003) Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 17:509–515

    Article  PubMed  CAS  Google Scholar 

  15. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53:108–114

    Article  PubMed  CAS  Google Scholar 

  16. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100:1539–1546

    Article  PubMed  Google Scholar 

  17. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635–639

    Article  PubMed  CAS  Google Scholar 

  18. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ (1991) Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1–3)IGF-I. Biochem J 276:547–554

    PubMed  CAS  Google Scholar 

  19. Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS (2005) Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol 204:687–692

    Article  PubMed  CAS  Google Scholar 

  20. Le Leu RK, Brown IL, Hu Y, Bird AR, Jackson M, Esterman A, Young GP (2005) A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J Nutr 135:996–1001

    PubMed  CAS  Google Scholar 

  21. Howarth GS, Xian CJ, Read LC (2000) Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors 18:119–133

    Article  PubMed  CAS  Google Scholar 

  22. Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344–1350

    PubMed  CAS  Google Scholar 

  23. Pelton NS, Tivey DR, Howarth GS, Davidson GP, Butler RN (2004) A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 39:1015–1016

    Article  PubMed  CAS  Google Scholar 

  24. Clarke JM, Pelton NC, Bajka BH, Howarth GS, Read LC, Butler RN (2006) Use of the 13C-Sucrose Breath Test to assess chemotherapy-induced small intestinal mucositis in the rat. Cancer Biol Ther 5:38–38

    Google Scholar 

  25. Sartor RB (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21:44–50

    PubMed  Google Scholar 

  26. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG (2004) Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 47:876–884

    Article  PubMed  Google Scholar 

  27. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB (2003) Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52:370–376

    Article  PubMed  CAS  Google Scholar 

  28. Moon G, Myung SJ, Jeong JY, Yang SK, Cho YK, Lee SM, Chang HS, Byeon JS, Lee YJ, Lee GH, et al (2004) [Prophylactic effect of Lactobacillus GG in animal colitis and its effect on cytokine secretion and mucin gene expressions]. Korean J Gastroenterol 43:234–245

    PubMed  Google Scholar 

  29. Zhang L, Li N, Caicedo R, Neu J (2005) Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr 135:1752–1756

    PubMed  CAS  Google Scholar 

  30. Shiba T, Aiba Y, Ishikawa H, Ushiyama A, Takagi A, Mine >T, Koga Y (2003) The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol 47:371–378

    PubMed  CAS  Google Scholar 

  31. McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK, et al (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975–980

    Article  PubMed  CAS  Google Scholar 

  32. Setoyama H, Imaoka A, Ishikawa H, Umesaki Y (2003) Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect 5:115–122

    Article  PubMed  Google Scholar 

  33. Guarner F (2003) Microecology as a target for therapeutic intervention in inflammatory bowel disease. Drugs 6:868–873

    Google Scholar 

  34. Kobayashi S, Nantz R, Kitamura T, Higashikubo R, Horikoshi N (2005) Combined inhibition of ext racellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation. Oncogene 24:3011–3019

    Article  PubMed  CAS  Google Scholar 

  35. Yan F, Polk DB (2002) Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277:50959–50965

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors acknowledge Kerry Lymn, Roger Yazbeck and John Allen for assistance with animal trials.

Author information

Authors and Affiliations

  1. Centre for Paediatric and Adolescent Gastroenterology, Children, Youth and Women’s Health Service, 72 King William Road, North Adelaide, South Australia, Australia

    Rasha Kamil, Mark S. Geier, Ross N. Butler & Gordon S. Howarth

  2. Discipline of Physiology, School of Molecular and Biomedical Sciences, The University of Adelaide, Adelaide, South Australia, Australia

    Rasha Kamil, Mark S. Geier, Ross N. Butler & Gordon S. Howarth

  3. Department of Paediatrics, School of Health Sciences, The University of Adelaide, Adelaide, South Australia, Australia

    Ross N. Butler & Gordon S. Howarth

Authors
  1. Rasha Kamil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S. Geier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ross N. Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gordon S. Howarth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gordon S. Howarth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamil, R., Geier, M.S., Butler, R.N. et al. Lactobacillus rhamnosus GG Exacerbates Intestinal Ulceration in a Model of Indomethacin-Induced Enteropathy. Dig Dis Sci 52, 1247–1252 (2007). https://doi.org/10.1007/s10620-006-9443-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9443-3

Keywords

Search

Navigation